DXS INTERNATIONAL PLC (AQSE: DXSP) Notification Of Director / PDMR Dealing

2025-11-11 11:31:25

(MENAFN- GlobeNewsWire - Nasdaq) DXS INTERNATIONAL PLC (AQSE: DXSP) Notification of Director / PDMR Dealing

DXS INTERNATIONAL PLC

The Board of DXS International plc (the“Company” or“DXSP), the AQSE Growth Market quoted clinical decision support developer and supplier of clinical decision support systems, has received notification that on 11 November, Mr Bob Sutcliffe, the Chairman, purchased 50,000 Ordinary Shares in the Company at a price of 1.30p per share.

Following this transaction Mr Sutcliffe and his wife's interest in DXS Ordinary Shares is 1,383,756 Ordinary Shares representing 2.16% of the issued share capital of the Company.

1	Details of the person discharging managerial responsibilities / person closely associated
a)	Name	Mr. Robert Sutcliffe
2	Reason for the notification
a)	Position/status	Chairman
b)	Initial notification /Amendment	Initial
3	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)	Name	DXS INTERNATIONAL PLC
b)	LEI	2138001R1KEUWTXEVJ44
4	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a)	Description of the financial instrument, type of instrument	Ordinary Shares of 0.33p each

Identification code	ISIN GB00B2Q6HZ92

b)	Nature of the transaction	Purchase of shares
c)	Price(s) and volume(s)
		Price(s)	Volume(s)
		1.30p	50,000
d)	Aggregated information

- Aggregated volume

- Price

e)	Date of the transaction	11 November 2025
f)	Place of the transaction	Aquis Stock Exchange

The Directors of DXS International plc accept responsibility for this announcement.

Contacts:

David Immelman DXS International plc	01252 719800
AQSE Corporate Broker and AQSE Corporate Advisor Hybridan LLP Claire Louise Noyce	020 3764 2341

Notes to Editors

About DXS:
DXS International presents up to date treatment guidelines and recommendations, from Clinical Commissioning Groups and other trusted NHS sources, to doctors, nurses and pharmacists in their workflow and during the patient consultation. This effective clinical decision support ultimately translates to improved healthcare outcomes delivered more cost effectively and which should significantly contribute towards the NHS achieving its projected efficiency savings.

Attachment

DXS Notification of Director PDMR Dealings_11 11 2025 Bob Sutcliffe

MENAFN11112025004107003653ID1110327992

Legal Disclaimer:
MENAFN provides the information “as is” without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the provider above.